Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 20, Issue 2, pp. 340-346
PubMed
Published By
Print ISSN
Online ISSN
History
- Received January 21, 2020
- Revision received July 7, 2020
- Accepted November 9, 2020
- Published first December 3, 2020.
Article Versions
- Previous version (December 3, 2020 - 07:09).
- You are viewing the most recent version of this article.
Copyright & Usage
©2020 American Association for Cancer Research.
Author Information
- Shang-Fan Yu#,
- Donna W. Lee#,
- Bing Zheng#,
- Geoffrey del Rosario,
- Douglas Leipold,
- Helen Booler,
- Fiona Zhong,
- Montserrat Carrasco-Triguero,
- Kyu Hong,
- Peter Yan,
- Rebecca K. Rowntree,
- Melissa M. Schutten,
- Thomas Pillow,
- Jack D. Sadowsky,
- Peter S. Dragovich, and
- Andrew G. Polson*
- ↵*Corresponding Author:
Andrew G. Polson, Genentech Research and Early Development, 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-5134; Fax: 650-225-6240; E-mail: polson{at}gene.com
↵#S.-F. Yu, D.W. Lee, and B. Zheng contributed equally to this article.
February 2021
Volume 20, Issue 2
Volume 20, Issue 2
An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models
Jump to section
Advertisement